DiabetologyNews.net

Diabetology Xagena

Search results for "Glycaemic control"

There is no convincing evidence that the newer class of diabetes drugs, known as glitazones or thiazolidinediones, offer real advantages over other diabetes drugs, when used on their own, concludes th ...


Liraglutide ( Victoza ) once daily is substantially better at controlling blood glucose in type 2 diabetes than is twice-daily Exenatide ( Byetta ). These are the findings of the LEAD-6 study.Liraglut ...


Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence.The aim of the study ( INTERVAL ) was to assess the feasibility of ...


Glucagon-like peptide-1 receptor agonists Exenatide ( Byetta ) and Liraglutide ( Victoza ) have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.The effic ...


Researchers have compared stepwise addition of bolus Insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately controlled on basal Insulin plus oral antidiabetic drugs. ...


Although carbohydrate counting is the recommended dietary strategy for achieving glycaemic control in people with type 1 diabetes mellitus, the advice is based on narrative review and grading of the a ...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1 ) receptor agonists and basal insulins. In DURATION-3, ...


Diabetes mellitus is a leading cause of chronic kidney disease ( CKD ) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macr ...


Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy for type 2 diabetes mellitus that could provide robust glucose-loweri ...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at the American Diabetes Association ( ADA ) 76th Scientific S ...